These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28916496)

  • 1. Designer bacteria as intratumoural enzyme biofactories.
    Lehouritis P; Hogan G; Tangney M
    Adv Drug Deliv Rev; 2017 Sep; 118():8-23. PubMed ID: 28916496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial-directed enzyme prodrug therapy.
    Lehouritis P; Springer C; Tangney M
    J Control Release; 2013 Aug; 170(1):120-31. PubMed ID: 23688772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs in medicinal chemistry and enzyme prodrug therapies.
    Walther R; Rautio J; Zelikin AN
    Adv Drug Deliv Rev; 2017 Sep; 118():65-77. PubMed ID: 28676386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing metal-contained enzyme mimics for prodrug activation.
    Du B; Li D; Wang J; Wang E
    Adv Drug Deliv Rev; 2017 Sep; 118():78-93. PubMed ID: 28412325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a genetically engineered E. coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model.
    Afkhami-Poostchi A; Mashreghi M; Iranshahi M; Matin MM
    Int J Pharm; 2020 Apr; 579():119159. PubMed ID: 32081798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate mediated enzyme prodrug therapy.
    Fejerskov B; Jarlstad Olesen MT; Zelikin AN
    Adv Drug Deliv Rev; 2017 Sep; 118():24-34. PubMed ID: 28457884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer.
    Hosseini-Giv N; Bahrami AR; Matin MM
    Int J Pharm; 2021 Sep; 606():120931. PubMed ID: 34310961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted bacteria-mediated therapy of mouse colorectal cancer using baicalin, a natural glucuronide compound, and E. coli overexpressing β-glucuronidase.
    Jafari B; Bahrami AR; Matin MM
    Int J Pharm; 2023 Jul; 642():123099. PubMed ID: 37271252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
    Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
    Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative bacterial vector.
    Chan-Hyams JVE; Ackerley DF
    MethodsX; 2020; 7():100797. PubMed ID: 32021829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
    Chen Z; Penet MF; Krishnamachary B; Banerjee SR; Pomper MG; Bhujwalla ZM
    Biomaterials; 2016 Feb; 80():57-67. PubMed ID: 26706476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives.
    Scomparin A; Florindo HF; Tiram G; Ferguson EL; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2017 Sep; 118():52-64. PubMed ID: 28916497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
    Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
    Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.
    Cheng CM; Chen FM; Lu YL; Tzou SC; Wang JY; Kao CH; Liao KW; Cheng TC; Chuang CH; Chen BM; Roffler S; Cheng TL
    Cancer Gene Ther; 2013 May; 20(5):276-81. PubMed ID: 23598434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.